BioWorld - Wednesday, February 11, 2026

Articles Tagged with ''Roche Group''

Neurology/Psychiatric

Roche divulges GABA-A receptor PAMs for neurological disorders

March 1, 2023
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested cyclopenta-thieno-diazepine derivatives acting as GABA-A receptor subunit α2β2γ1 positive allosteric modulators (PAMs). As such, they are reported to be useful for the treatment of neurological disorders.
Read More
Neurology/Psychiatric

Roche discovers new legumain inhibitors

Feb. 24, 2023
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described haloacethydrazide compounds acting as legumain (asparaginyl endopeptidase; LGMN; AEP) inhibitors reported to be useful for the treatment of subacute sclerosing panencephalitis, progressive supranuclear palsy, frontotemporal dementia and Alzheimer's disease, among others.
Read More
Top 100 Global innovators 2022

Two pharmas and a med-tech crack Clarivate’s list of the top innovators worldwide

Feb. 24, 2022
By Lee Landenberger
Three companies from the pharmaceutical and med-tech sectors are among this year’s most influential innovators, according to the newest edition of Clarivate plc’s Top 100 Global Innovators 2022. The pharmaceutical companies that were found to be the most innovative in the top 100 list are Johnson & Johnson, of New Brunswick, N.J., and Roche AG, of Basel, Switzerland. Royal Philips NV, of Amsterdam, was found to be the most innovative med-tech company in the top 100.
Read More